Epigenetic therapy for Friedreich ataxia
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Objective: To investigate whether a histone deacetylase inhibitor (HDACi) would be effective in an in vitro model for the neurodegenerative disease Friedreich ataxia (FRDA) and to evaluate safety and surrogate markers of efficacy in a phase I clinical trial in patients. Methods: We used a human FRDA neuronal cell model, derived from patient induced pluripotent stem cells, to determine the efficacy of a 2‐aminobenzamide HDACi (109) as a modulator of FXN gene expression and chromatin histone modifications. FRDA patients were dosed in 4 cohorts, ranging from 30mg/day to 240mg/day of the formulated drug product of HDACi 109, RG2833. Patients were monitored for adverse effects as well as for increases in FXN mRNA, frataxin protein, and chromatin modification in blood cells. Results: In the neuronal cell model, HDACi 109/RG2833 increases FXN mRNA levels and frataxin protein, with concomitant changes in the epigenetic state of the gene. Chromatin signatures indicate that histone H3 lysine 9 is a key residue for gene silencing through methylation and reactivation through acetylation, mediated by the HDACi. Drug treatment in FRDA patients demonstrated increased FXN mRNA and H3 lysine 9 acetylation in peripheral blood mononuclear cells. No safety issues were encountered. Interpretation: Drug exposure inducing epigenetic changes in neurons in vitro is comparable to the exposure required in patients to see epigenetic changes in circulating lymphoid cells and increases in gene expression. These findings provide a proof of concept for the development of an epigenetic therapy for this fatal neurological disease. Ann Neurol 2014;76:489–508
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Friedreich's Ataxia: Autosomal Recessive Disease Caused by an Intronic GAA Triplet Repeat Expansion
Campuzano, V., Montermini, L., Moltò, M. D., Pianese, L., Cossée, M., Cavalcanti, F., Monros, E., Rodius, F., Duclos, F., Monticelli, A., et al. (1996) · Science · doi:10.1126/science.271.5254.1423 · Cited by 2,786 · cited 1×
“At the molecular level, >95% of FRDA patients carry a GAA•TTC trinucleotide repeat expansion in the first intron of the FXN gene,(4) leading to heterochromatinmediated transcriptional repression and reduction of the essential mitochondrial protein frataxin.(4) Frataxin is a”
BackgroundSelf-citationInduced pluripotent stem cells from a spinal muscular atrophy patient
Ebert, A. D., Yu, J., Rose, F. F., Mattis, V. B., Lorson, C. L., Thomson, J. A., & Svendsen, C. N. (2009) · Nature · doi:10.1038/nature07677 · Cited by 1,441
Cooper, O., Seo, H., Andrabi, S., Guardia-Laguarta, C., Graziotto, J., Sundberg, M., McLean, J. R., Carrillo-Reid, L., Xie, Z., Osborn, T., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003985 · Cited by 508
Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia
Herman, D., Jenssen, K., Burnett, R., Soragni, E., Perlman, S. L., & Gottesfeld, J. M. (2006) · Nature Chemical Biology · doi:10.1038/nchembio815 · Cited by 442 · cited 8×
“Here we demonstrate that HDAC inhibition in vitro via 109(13) (under the development name of RG2833 for the formulated drug product) in FRDA neurons derived from patient iPSCs reverses FXN gene silencing to a degree comparable to that found in previous studies employing human PBMCs and mouse models.(6,13,16,17) In the…”
BackgroundMethodResultSelf-citationBidichandani, S. I., Ashizawa, T., & Patel, P. I. (1998) · The American Journal of Human Genetics · doi:10.1086/301680 · Cited by 381
Pimelic Diphenylamide 106 Is a Slow, Tight-binding Inhibitor of Class I Histone Deacetylases
Chou, C. J., Herman, D., & Gottesfeld, J. M. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m807045200 · Cited by 223 · cited 2×
“We previously reported that 2-aminobenzamides differed from HDAC inhibitors that failed to activate FXN gene expression in terms of their inhibitory mechanism, where the active molecules inhibit their target enzymes through a slow-on/slow-off mechanism.(29) It is likely that the 4- and 5-substituted 2-aminobenzamides…”
BackgroundSelf-citationAdvances in understanding the molecular basis of FXTAS
Garcia-Arocena, D., & Hagerman, P. J. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq166 · Cited by 136
Qiang, L., Fujita, R., & Abeliovich, A. (2013) · Neuron · doi:10.1016/j.neuron.2013.06.002 · Cited by 59 · cited 1×
“This approach can potentially be used to test other therapeutics for FRDA and for neurological disorders in general.(37) Furthermore, because we assayed cellular responses at a relatively early stage of neuronal differentiation, we are able to exploit the mitotically active nature of differentiated neural stem cells a…”
Background
Cited by
Pluripotent stem cells in disease modelling and drug discovery
Avior, Y., Sagi, I., & Benvenisty, N. (2016) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2015.27 · Cited by 592
Recent developments of HDAC inhibitors: Emerging indications and novel molecules
Bondarev, A. D., Attwood, M. M., Jonsson, J., Chubarev, V. N., Tarasov, V. V., & Schiöth, H. B. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14889 · Cited by 416
Romano, S., Coarelli, G., Marcotulli, C., Leonardi, L., Piccolo, F., Spadaro, M., Frontali, M., Ferraldeschi, M., Vulpiani, M. C., Ponzelli, F., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00201-x · Cited by 212
Nabhan, J. F., Wood, K. M., Rao, V. P., Morin, J., Bhamidipaty, S., LaBranche, T. P., Gooch, R. L., Bozal, F., Bulawa, C. E., & Guild, B. C. (2016) · Scientific Reports · doi:10.1038/srep20019 · Cited by 140
Pharmacological treatments for Friedreich ataxia
Kearney, M., Orrell, R. W., Fahey, M., Brassington, R., & Pandolfo, M. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007791.pub4 · Cited by 74
Self-citation
Metadata
- Authors
- Soragni, E., Miao, W., Iudicello, M., Jacoby, D., De Mercanti, S., Clerico, M., Longo, F., Piga, A., Ku, S., Campau, E., Du, J., Penalver, P., Rai, M., Madara, J. C., Nazor, K., O'Connor, M., Maximov, A., Loring, J. F., Pandolfo, M., Durelli, L., Gottesfeld, J. M., & Rusche, J. R.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2014-09-16
- Volume
- 76
- Issue
- 4
- Pages
- 489-508
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2142275018
- Cited by
- 154
- References
- 8
- FWCI
- 6.98
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.